SPY330.30+3.33 1.02%
DIA272.81+1.37 0.50%
IXIC10,963.64+184.84 1.71%

Raymond James Initiates Coverage On Sarepta Therapeutics with Outperform Rating, Announces Price Target of $200

Raymond James analyst Danielle Brill initiates coverage on Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform rating and announces Price Target of $200.

Benzinga · 08/25/2020 10:33
Raymond James analyst Danielle Brill initiates coverage on Sarepta Therapeutics (NASDAQ: SRPT) with a Outperform rating and announces Price Target of $200.